Vir Biotechnology
226 hedge funds and large institutions have $2.23B invested in Vir Biotechnology in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 88 increasing their positions, 73 reducing their positions, and 34 closing their positions.
35% more capital inflows, than outflows
Capital inflows: $240M | Capital outflows: $179M
21% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 73
1.52% more ownership
Funds ownership: 66.25% → 67.77% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 34
3% less funds holding
Funds holding: 232 → 226 (-6)
55% less call options, than puts
Call options by funds: $14.4M | Put options by funds: $32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$45.6M |
| 2 |
Paradigm Biocapital Advisors
New York
|
+$25.5M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$24.6M |
| 4 |
Walleye Capital
New York
|
+$21.7M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB Investment Advisers (UK)
London,
United Kingdom
|
-$41.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$29.4M |
| 3 |
Temasek Holdings
Singapore
|
-$17.1M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$7.35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.75M |
VIR Hedge Fund Activity: Q2 2023 in Review
226 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2023, worth a combined $2.23B — up 8.2% from $2.06B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of VIR and 31 opened new positions — a net loss of 3 holders — while 73 trimmed existing stakes and 88 added.
The largest buyer was Perceptive Advisors, adding an estimated $45.6M. The largest seller was SB Investment Advisers (UK), cutting an estimated $41.1M.
- 226 institutional investors held Vir Biotechnology (VIR) as of Q2 2023, down from 232 in Q1 2023.
- Funds reported $2.23B of Vir Biotechnology stock for Q2 2023, up 8.2% quarter-over-quarter.
- 31 funds opened new Vir Biotechnology positions in Q2 2023 and 34 closed out, a net change of -3 holders.
- The largest Vir Biotechnology buyer in Q2 2023 was Perceptive Advisors, an estimated $45.6M added.
- The largest Vir Biotechnology seller in Q2 2023 was SB Investment Advisers (UK), an estimated $41.1M sold.
Based on aggregated 13F filings for Q2 2023.